Balfour Beatty plc (LON:BBY – Get Free Report)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 413.32 ($5.22) and traded as high as GBX 463.40 ($5.85). Balfour Beatty shares last traded at GBX 454.20 ($5.73), with a volume of 606,634 shares.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft boosted their target price on Balfour Beatty from GBX 500 ($6.31) to GBX 575 ($7.26) and gave the company a “buy” rating in a research note on Friday, November 22nd.
Get Our Latest Stock Report on Balfour Beatty
Balfour Beatty Stock Performance
Insider Buying and Selling
In other Balfour Beatty news, insider Robert MacLeod bought 17,674 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average price of GBX 422 ($5.33) per share, with a total value of £74,584.28 ($94,136.41). Also, insider Leo Quinn sold 317,071 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of GBX 448 ($5.65), for a total transaction of £1,420,478.08 ($1,792,853.82). Company insiders own 1.15% of the company’s stock.
Balfour Beatty Company Profile
Balfour Beatty plc finances, designs, develops, builds, and maintains infrastructure in the United Kingdom, the United States, and internationally. It operates through three segments: Construction Services, Support Services, and Infrastructure Investments. The company constructs buildings, including commercial, healthcare, education, retail, and residential assets; and infrastructure assets comprising highways and railways, as well as other large-scale infrastructure assets, such as waste, water, and energy plants.
Featured Articles
- Five stocks we like better than Balfour Beatty
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Canada Bond Market Holiday: How to Invest and Trade
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Conference Calls and Individual Investors
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Balfour Beatty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balfour Beatty and related companies with MarketBeat.com's FREE daily email newsletter.